Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $16.80

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have received an average rating of “Hold” from the five research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $16.80.

A number of equities research analysts have recently issued reports on HCM shares. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a research report on Thursday, May 28th. Wall Street Zen downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 1st. Finally, Bank of America reduced their price target on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in shares of HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares in the last quarter. M&G PLC increased its stake in shares of HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after purchasing an additional 54,601 shares in the last quarter. Amundi increased its stake in shares of HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares in the last quarter. Jane Street Group LLC increased its stake in shares of HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of HUTCHMED by 112.8% during the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after purchasing an additional 72,614 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Price Performance

HCM stock opened at $10.96 on Wednesday. The firm has a 50 day moving average of $13.11 and a 200-day moving average of $13.93. HUTCHMED has a 12-month low of $10.40 and a 12-month high of $19.50. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.